Impact of Lemborexant on Daytime Sleepiness/Alertness in Participants With Comorbid Insomnia and Mild Obstructive Sleep Apnea (P9-4.004)
This post hoc analysis assessed the impact of lemborexant (LEM), a dual orexin-receptor antagonist approved to treat insomnia in adults, on morning sleepiness/alertness in participants with comorbid insomnia and mild obstructive sleep apnea (COMISA).
Authors
- Fiona Gardiner
- Jocelyn Y. Cheng (ORCID: https://orcid.org/0000-0001-5318-5668)
- Margaret Moline (ORCID: https://orcid.org/0000-0003-0807-2167)
- Mark I. Boulos (ORCID: https://orcid.org/0000-0002-9547-1889)
- Dinesh Kumar (ORCID: https://orcid.org/0000-0002-5003-399X)
Institutions
- Sunnybrook Health Science Centre (CA)
- Health Sciences Centre (CA)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208838
- Primary Topic
- Sleep and related disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00